|
2023 Journal Article Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatmentKhoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000 |
|
2023 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction studyPeyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., Dignass, Axel, Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego ... QUASAR Study Group (2023). Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology, 165 (6), 1443-1457. doi: 10.1053/j.gastro.2023.08.038 |
|
2023 Journal Article Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epitheliaMann, Zoya, Lim, Fayth, Verma, Suzie, Nanavati, Bageshri N., Davies, Julie M., Begun, Jakob, Hardeman, Edna C., Gunning, Peter W., Subramanyam, Deepa, Yap, Alpha S. and Duszyc, Kinga (2023). Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia. Molecular Biology of the Cell, 35 (1) br3, 1-12. doi: 10.1091/mbc.e23-08-0337 |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
|
2023 Journal Article Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel diseaseEwais, Tatjana, Begun, Jakob and Laakso, E-Liisa (2023). Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease. Biomedicines, 11 (8) 2179, 1-11. doi: 10.3390/biomedicines11082179 |
|
2023 Journal Article Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitisGilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115 |
|
2023 Journal Article Upadacitinib induction and maintenance therapy for Crohn's diseaseLoftus, Edward V., Panés, Julian, Lacerda, Ana P., Peyrin-Biroulet, Laurent, D'Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid S., Phillips, Charles, Mohamed, Mohamed-Eslam F, Liu, Jianzhong, Geng, Ziqian, Feng, Tian, Dubcenco, Elena and Colombel, Jean-Frederic (2023). Upadacitinib induction and maintenance therapy for Crohn's disease. The New England journal of medicine, 388 (21), 1966-1980. doi: 10.1056/NEJMoa2212728 |
|
2023 Journal Article Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialFeagan, Brian G, Sands, Bruce E, Sandborn, William J, Germinaro, Matthew, Vetter, Marion, Shao, Jie, Sheng, Shihong, Johanns, Jewel, Panés, Julián, Tkachev, Alexander, Kalimullina, Dilara, Petryka, Robert, Osipenko, Marina, Tsarynna, Nataliia, Bilianskyi, Leonid, Kleczkowski, Dariusz, Yurkiv, Andrii, Woynarowski, Marek, Abrahamovych, Orest, Ivanishyn, Olha, Rydzewska, Grazyna, Kierkus, Jaroslaw, Petrova, Elina, Vasilevskaya, Olga, Afanasieva, Halyna, Francesconi, Carlos, Leszczyszyn, Jaroslaw, Bunkova, Elena, Platonov, Dmitry ... for the VEGA Study Group (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. The Lancet Gastroenterology and Hepatology, 8 (4), 307-320. doi: 10.1016/S2468-1253(22)00427-7 |
|
2023 Journal Article Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liverAlabbas, Saleh Y., Giri, Rabina, Oancea, Iulia, Davies, Julie, Schreibner, Veronika, Florin, Timothy H. and Begun, Jakob (2023). Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver. Journal of Gastroenterology and Hepatology, 38 (4), 609-618. doi: 10.1111/jgh.16102 |
|
2023 Journal Article Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancerLyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127 |
|
2023 Journal Article An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitisMortlock, Sally, Lord, Anton, Montgomery, Grant, Zakrzewski, Martha, Simms, Lisa A, Krishnaprasad, Krupa, Hanigan, Katherine, Doecke, James D, Walsh, Alissa, Lawrance, Ian C, Bampton, Peter A, Andrews, Jane M, Mahy, Gillian, Connor, Susan J, Sparrow, Miles P, Bell, Sally, Florin, Timothy H., Begun, Jakob, Gearry, Richard B and Radford-Smith, Graham L. (2023). An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 17 (2), 277-288. doi: 10.1093/ecco-jcc/jjac121 |
|
2022 Journal Article Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosisMalloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140, e252140. doi: 10.1136/bcr-2022-252140 |
|
2022 Journal Article MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axisSheng, Yong H., Davies, Julie M., Wang, Ran, Wong, Kuan Yau, Giri, Rabina, Yang, Yuanhao, Begun, Jakob, Florin, Timothy H., Hasnain, Sumaira Z. and McGuckin, Michael A. (2022). MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis. Cellular and Molecular Gastroenterology and Hepatology, 14 (4), 789-811. doi: 10.1016/j.jcmgh.2022.06.010 |
|
2022 Journal Article GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infectionLamba, M., Tiwari, N., Remedios, M., Begun, J., Christensen, B., Bollipo, S. and Devereaux, B. (2022). GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection. Journal of Gastroenterology and Hepatology (Australia), 37 (7), 1400-1401. doi: 10.1111/jgh.15873 |
|
2022 Journal Article Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialSands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob ... Zdena, Zadorova (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet, 399 (10342), 2200-2211. doi: 10.1016/S0140-6736(22)00688-2 |
|
2022 Journal Article The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisCheon, Jae Hee, Paridaens, Kristine, Awadhi, Sameer Al, Begun, Jakob, Fullarton, John R, Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Dignass, Axel U and Travis, Simon PL (2022). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi: 10.5217/ir.2022.00006 |
|
2022 Journal Article Secreted NF-κB suppressive microbial metabolites modulate gut inflammationGiri, Rabina, Hoedt, Emily C., Khushi, Shamsunnahar, Salim, Angela A., Bergot, Anne-Sophie, Schreiber, Veronika, Thomas, Ranjeny, McGuckin, Michael A., Florin, Timothy H., Morrison, Mark, Capon, Robert J., Ó Cuív, Páraic and Begun, Jakob (2022). Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 39 (2) 110646, 110646. doi: 10.1016/j.celrep.2022.110646 |
|
2022 Journal Article Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisLouis, Edouard, Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Dignass, Axel U, Magro, Fernando, Márquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Freddi, Matthew J and Travis, Simon Pl (2022). Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 9 (1) e000853, e000853. doi: 10.1136/bmjgast-2021-000853 |
|
2022 Journal Article Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophagesTran, Thao Thanh, Mathmann, Carmen D., Gatica-Andrades, Marcela, Rollo, Rachel F., Oelker, Melanie, Ljungberg, Johanna K., Nguyen, Tam T. K., Zamoshnikova, Alina, Kummari, Lalith K., Wyer, Orry J. K., Irvine, Katharine M., Melo-Bolívar, Javier, Gross, Annette, Brown, Darren, Mak, Jeffrey Y. W., Fairlie, David P., Hansford, Karl A., Cooper, Matthew A., Giri, Rabina, Schreiber, Veronika, Joseph, Shannon R., Simpson, Fiona, Barnett, Timothy C., Johansson, Jörgen, Dankers, Wendy, Harris, James, Wells, Timothy J., Kapetanovic, Ronan, Sweet, Matthew J. ... Blumenthal, Antje (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 18 (1) e1010166, e1010166. doi: 10.1371/journal.ppat.1010166 |
|
2022 Journal Article Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of ColitisMovva, Ramya, Murtaza, Nida, Giri, Rabina, Png, Chin Wen, Davies, Julie, Alabbas, Saleh, Oancea, Iulia, O'Cuiv, Páraic, Morrison, Mark, Begun, Jakob and Florin, Timothy H. (2022). Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. Gastro Hep Advances, 1 (3), 359-374. doi: 10.1016/j.gastha.2021.12.008 |
